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2214-0247/Copyright ª 2014, TaiwanAbstract Adiponectin is considered a modulator of glucose metabolism. Hypoadiponectine-
mia was reported to be associated with glucose metabolism and metabolic syndrome, and
had been found in patients with hepatitis B virus (HBV) and hepatitis C virus infections. How-
ever, little is known about the role of adiponectin in patients with HBV infection. Fifty-five pa-
tients with HBV infection and 52 healthy individuals were included in this study. We found that
serum adiponectin was significantly lower in patients with HBV infection. We also found that
HBV-infected patients with hemoglobin A1C 6.5% had a lower adiponectin level than those
with hemoglobin A1C <6.5%. In conclusion, hypoadiponectinemia occurs in patients with
HBV infection, and adiponectin may play a role in the pathogenesis of glucose metabolism
in these patients.
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Genomic Medicine and BiomarkerIntroduction
Adiponectin is a protein produced by adipocytes. It is
considered a modulator of glucose metabolism.1,2 Hypo-
adiponectinemia was reported to be closely associated with
metabolic syndrome.3,4 It had also been found in patients
with hepatitis B virus (HBV) and hepatitis C virus (HCV)Society. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Standardized levels of (A) fasting glucose and (B)
HbA1c in Group 2 HBV-infected patients were significantly
higher than those in the control group. *p < 0.001.
HbA1c Z hemoglobin A1C; HBV Z hepatitis B virus.
Figure 2 Standardized level of adiponectin was significantly
lower in both Group 1 and Group 2 HBV-infected patients,
compared with the control group. *p < 0.001. HBVZ hepatitis
B virus.
Adiponectin and glucose in HBV patients 181infections5,6; however, little is known about the role of
adiponectin in patients with HBV infection. Therefore, we
conducted this study to assay the serum concentration of
adiponectin, and to evaluate the correlation between
serum adiponectin and glucose in patients with HBV
infection.
Materials and methods
From April 1, 2013 to September 30, 2013, 55 patients with
HBV infection and 52 healthy individuals without hepatitis
and diabetes (control group) were included in the study.
Patients with HBV infection were further divided into two
groups according to the concentration of hemoglobin A1C
(HbA1c): Group 1 (HbA1c <6.5%; 47 patients) and Group 2
(HbA1c 6.5%; 8 patients). All participants underwent
serum fasting glucose, HbA1c, and adiponectin examina-
tions. The result was divided by the average concentration
of the control group, and the ratio was considered as the
standardized level. The value of each test was compared
with the Student t test and the folded difference was
determined.
Results
The standardized levels of fasting glucose and HbA1c in
Group 2 HBV-infected patients were significantly higher
than those in the control group (p < 0.001; Fig. 1). The
standardized level of adiponectin was significantly lower in
both Group 1 and Group 2 HBV-infected patients, compared
with the control group (p < 0.001). The standardized level
of adiponectin was lower in Group 2 patients than in Group
1 patients (p Z 0.832; Fig. 2)
Discussion
Adiponectin, an adipokine synthesized and secreted by
adipocytes, has potent anti-inflammatory and antidia-
betic properties. It can stimulate insulin secretion, in-
crease insulin sensitivity, and control obesity.1,7,8 It is
also associated with insulin resistance.9 Hypo-
adiponectinemia is reported to be associated with
metabolic syndrome.3,4
Studies suggested that HCV infection is closely related
to the metabolic syndrome.5,10 Grigorescu et al5 found
significantly lower levels of adiponectin in patients with
HCV infection and metabolic syndrome. However, little is
known about the role of adiponectin in patients with
HBV infection. Our previous report demonstrated that
HBV infection correlated with hyperglycemia.11 In this
study, we found that serum adiponectin was significantly
lower in patients with HBV infection, which is in agree-
ment with the results of previous studies.4,6 We also
found that HBV-infected patients with HbA1c 6.5% had
a lower adiponectin level than those with HbA1c <6.5%.
Although it revealed no statistical significance
(p Z 0.832), further studies with a large sample size are
needed to find the exact significance, which may help
understand the role of adiponectin in glucose
metabolism.
182 W.-T. Hsu et al.In conclusion, hypoadiponectinemia occurs in patients
with HBV infection, and adiponectin may play a role in the
pathogenesis of glucose metabolism in these patients.
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